GHRP-6 and Ipamorelin Interaction: Compatible | Peptide Database

Many peptides discussed on this website are research chemicals that are not approved by the FDA for human use. Information about dosing, effects, and protocols is derived from published research studies, clinical trials, and user reports. This information is provided for educational purposes only.

Join others researching Winstrol — share findings, ask questions, and learn from real experiences Winstrol is the brand name for stanozolol, a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It was developed in 1962 by Winthrop Laboratories and approved by the FDA for the treatment of hereditary angioedema, a condition characterized by episodic swelling of the face, extremities, genitals, bowel wall, and upper airway. Stanozolol is structurally unique among DHT derivatives due to the addition of a pyrazole group fused to the A-ring, which significantly alters its pharmacological profile. It possesses a high anabolic-to-androgenic ratio (320:30 relative to methyltestosterone), making it one of the more anabolic oral steroids available. Winstrol does not aromatize to estrogen, producing no estrogenic side effects such as water retention or gynecomastia, which has made it a staple compound in cutting and pre-contest bodybuilding protocols. It is available in both oral tablet and injectable aqueous suspension forms, with both preparations being 17-alpha-alkylated and therefore hepatotoxic. Winstrol gained widespread notoriety after sprinter Ben Johnson tested positive for it following his gold medal performance at the 1988 Seoul Olympics, which remains one of the most publicized doping cases in sports history. Stanozolol exerts its effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and red blood cell production. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, eliminating estrogen-mediated side effects. The pyrazole modification to the A-ring distinguishes stanozolol from other DHT derivatives by enhancing its oral bioavailability and altering its receptor binding characteristics. Stanozolol has a notable effect on sex hormone-binding globulin (SHBG), suppressing it more potently than most other anabolic steroids, which increases the fraction of free (bioactive) testosterone and other steroids in circulation. This SHBG-lowering property makes it particularly effective when stacked with other compounds. Stanozolol also stimulates collagen synthesis, though paradoxically it is associated with joint discomfort, likely due to its potent anti-estrogenic environment reducing synovial fluid production. It increases erythropoiesis through enhanced erythropoietin production, contributing to improved oxygen delivery. In hereditary angioedema, stanozolol increases serum levels of C1-esterase inhibitor and C4 complement, reducing the frequency and severity of angioedema attacks through a mechanism distinct from its anabolic properties.